Intralytix, Inc., announced today that is has entered into a joint collaboration agreement with the Eliava Foundation and Ferring Pharmaceuticals to develop and commercialize new and innovative bacteriophage-based drugs in the field of Reproductive Medicine […]
Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company applying synthetic biology to beneficial microbes to develop novel, living medicines and Ginkgo Bioworks, the organism company, today announced a platform collaboration to accelerate expansion and development of […]
BiomX Ltd., a microbiome company developing both natural and engineered phage therapies, today announced it has licensed a new set of bacterial targets from JSR Corporation, for the development and commercialization of phage therapies for […]
Whole Biome, an evidence-based microbiome company, today announced that it has secured $35 million in Series B financing. The round was led by existing investor Sequoia Capital with repeat participation from True Ventures, Khosla Ventures, […]
Crown Laboratories, Inc. (“Crown”), a leading, fully integrated skin care company, announced it has acquired Xycrobe Therapeutics, Inc. (“Xycrobe”). Xycrobe’s technology focuses on utilizing the ubiquitous nature of skin microbes by turning them into vehicles […]
Synlogic, Inc., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced a new clinical collaboration with Roche (SIX:RO, ROG), to explore Synlogic’s Synthetic Biotic™ medicine, SYNB1891, […]
MaaT Pharma announced today that the Institut National de la Propriété Industrielle (INPI), the French Patent Office, has issued three new patents to the company covering its sample collection device and the overall processes associated […]
Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, has raised an additional $18.5 million as an extension of its Series C […]
Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today provided an operational update and reported financial results for the […]
Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, announced that the Opposition Division of the European Patent Office has upheld Vedanta’s […]